EMEA Approvals - Xarelto To Enter Lucrative Oral Anticoagulant Market

Bayer Healthcare's oral anticoagulant, Xarelto (rivaroxaban), has been recommended for EU marketing authorisation by the European Medicine Agency (EMEA)'s Committee for Products for Human Use (CHMP) in the agency's monthly appraisal meeting for July 2008. European Commission (EC) approval - which is likely to follow in the next couple of months - would allow the product to be used for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery, pitching the product against rival Boehringer Ingelheim's recently approved Pradaxa (dabigatran

To read the full article, please choose one of the following options: